Dai, Z., Yan, Y., Huang, L. (2025). Polatuzumab vedotin retains potent activity against CD79B mutations: Preclinical and clinical efficacy in diffuse large B-cell lymphoma. Blood. https://doi.org/10.1182/blood-2025-1923